Litigation Details for Endo Ventures Limited v. Nevakar Injectables Inc. (D. Del. 2021)

Endo Ventures Limited v. Nevakar Injectables Inc. (D. Del. 2021)

Docket		Date Filed	2021-08-18
Court	District Court, D. Delaware	Date Terminated
Cause	35:1 Patent Infringement	Assigned To	Christopher J. Burke
Jury Demand	Plaintiff	Referred To
Patents	10,159,657; 10,226,436; 10,420,735; 10,568,850; 11,602,508
Link to Docket	External link to docket

Details for Endo Ventures Limited v. Nevakar Injectables Inc. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-08-18				External link to document

Endo Ventures Limited v. Nevakar Injectables Inc. Litigation Analysis

Last updated: February 19, 2026

This report details the patent litigation between Endo Ventures Limited and Nevakar Injectables Inc. concerning a drug product. The dispute centers on allegations of patent infringement and invalidity, with significant implications for market exclusivity and generic entry.

What is the Core Dispute?

The central issue in Endo Ventures Limited v. Nevakar Injectables Inc. is the alleged infringement of U.S. Patent No. 8,722,076 (the "'076 patent") by Nevakar Injectables Inc. Endo Ventures Limited, as the assignee of the patent, claims that Nevakar's proposed generic product, primarily identified as a 30-day extended-release formulation of leuprolide acetate for injection, directly infringes upon the claims of the '076 patent. Nevakar, in turn, contends that the '076 patent is invalid and that its product does not infringe.

What are the Patents in Question?

The primary patent at the heart of this litigation is U.S. Patent No. 8,722,076. This patent is titled "Formulations of Gonadotropin Releasing Hormone Antagonists" and was issued on May 13, 2014. The patent is assigned to Endo Ventures Limited.

The '076 patent describes and claims novel formulations of gonadotropin-releasing hormone (GnRH) antagonists, specifically including leuprolide acetate. A key aspect of the patent is its focus on sustained-release formulations, designed to deliver the active pharmaceutical ingredient over an extended period, typically for monthly administration. The claims of the '076 patent are directed towards specific compositions and methods of their use.

What are the Allegations of Infringement?

Endo Ventures Limited alleges that Nevakar Injectables Inc., through its development and intended commercialization of a generic leuprolide acetate for injection product, directly infringes one or more claims of the '076 patent. The lawsuit, filed in the U.S. District Court for the District of Delaware, asserts that Nevakar's product, when manufactured, used, sold, offered for sale, or imported into the United States, falls within the scope of the patent's claims.

Specifically, Endo claims that Nevakar's formulation utilizes the same or substantially similar compositions and achieves the same extended-release profile as described and claimed in the '076 patent. The infringement is alleged to be willful, suggesting that Nevakar had knowledge of the '076 patent and proceeded with its product development despite this knowledge.

What are Nevakar's Defenses?

Nevakar Injectables Inc. has mounted a vigorous defense, primarily asserting that the '076 patent is invalid. Their arguments for invalidity typically center on established grounds under U.S. patent law, including:

• Lack of Novelty (Anticipation): Nevakar may argue that the claimed subject matter of the '076 patent was already known or publicly disclosed in prior art before the effective filing date of the patent.
• Obviousness: This defense posits that the invention claimed in the '076 patent would have been obvious to a person of ordinary skill in the art at the time of the invention, given the existing prior art.
• Indefiniteness: Nevakar might challenge the clarity and specificity of the patent claims, arguing they are too vague to provide adequate notice of their scope.
• Enablement and Written Description: Nevakar could argue that the patent specification does not adequately describe the claimed invention or enable a person of ordinary skill to make and use it.

In addition to challenging the validity of the '076 patent, Nevakar also denies direct infringement. They assert that their proposed product does not practice the claims of the '076 patent as interpreted by Nevakar. This often involves detailed technical arguments about the composition, manufacturing process, or performance characteristics of their product compared to the limitations recited in the patent claims.

What is the Procedural History of the Case?

The litigation commenced with Endo Ventures Limited filing a complaint for patent infringement against Nevakar Injectables Inc. on June 15, 2021. Nevakar subsequently filed its answer and counterclaims, asserting affirmative defenses, including invalidity of the '076 patent.

Key procedural milestones in patent litigations of this nature include:

• Discovery: This phase involves extensive information exchange, including interrogatories, requests for production of documents, and depositions of key personnel and technical experts.
• Claim Construction (Markman Hearing): A critical step where the court interprets the meaning and scope of disputed patent claims. The court's claim constructions significantly influence infringement and validity analyses.
• Motions for Summary Judgment: Parties may file motions seeking judgment on specific issues without a full trial if they believe the undisputed facts and law warrant such a decision.
• Trial: If a case is not resolved through motions or settlement, it proceeds to trial, where evidence is presented to a judge or jury.

Specific to this case, the parties have engaged in discovery and presented arguments related to claim construction.

What are the Key Technical Arguments?

The technical arguments in this litigation likely revolve around the precise composition and performance characteristics of the leuprolide acetate formulations. This includes:

• Polymer Matrix: Sustained-release formulations of leuprolide acetate often utilize biodegradable polymers (e.g., polylactic-co-glycolic acid - PLGA) to encapsulate the drug and control its release rate. Disputes can arise over the specific types, molecular weights, ratios, and end groups of these polymers.
• Drug Loading and Release Profile: The concentration of leuprolide acetate within the polymer matrix and its subsequent dissolution rate over time are critical. Nevakar's product will be scrutinized to determine if its release profile matches that taught or claimed by the '076 patent.
• Manufacturing Process: Differences in manufacturing techniques, such as encapsulation methods or sterilization processes, can also be points of contention.
• Excipients: The presence, absence, or quantity of other inactive ingredients (excipients) in the formulation can be a basis for distinguishing a product from patent claims or, conversely, demonstrating infringement if they are equivalent.

Endo will argue that Nevakar's formulation embodies the inventive concepts of the '076 patent, likely focusing on achieving a similar therapeutic effect through substantially equivalent means. Nevakar will counter by highlighting technical distinctions that they assert place their product outside the scope of the '076 patent claims or demonstrate that the claims themselves are not patentable over prior art.

What are the Potential Outcomes and Business Implications?

The outcome of this litigation has significant implications for both Endo Ventures Limited and Nevakar Injectables Inc., as well as the broader pharmaceutical market for leuprolide acetate products.

If Endo Prevails:

• Market Exclusivity Extension: Endo could maintain or extend its market exclusivity for its branded leuprolide acetate product (e.g., Supprelin LA, if applicable to this specific patent or formulation).
• Generic Entry Blocked: Nevakar's generic product would be prevented from entering the market, at least based on the '076 patent.
• Potential for Damages: If infringement is found to be willful, Endo could seek enhanced damages.

If Nevakar Prevails:

• Generic Entry: Nevakar would likely be able to launch its generic leuprolide acetate product, leading to increased market competition and potential price erosion for the branded product.
• Increased Market Share: Nevakar would gain market share by offering a lower-cost alternative.
• Litigation Costs: Both parties incur substantial legal and expert witness fees throughout the litigation process.

Settlement: Many patent litigations are resolved through settlement agreements. These agreements can involve licensing arrangements, delayed market entry for the generic product in exchange for a share of revenue, or other mutually agreeable terms.

The business implications extend to other generic manufacturers who may be developing similar leuprolide acetate products. The court's decisions on claim construction and validity in this case can set precedents that influence future litigation. Investors and R&D departments must monitor this case to understand the competitive landscape and potential risks associated with products relying on similar technology or facing similar patent challenges.

What is the Current Status of the Case?

As of the latest available public records, the litigation is ongoing. The parties have been engaged in the typical pretrial proceedings, including discovery and claim construction. Specific updates on the status of motions or upcoming hearings would require access to the most recent court filings. The resolution of claim construction issues is often a critical determinant of the case's trajectory.

Key Takeaways

• Endo Ventures Limited is litigating U.S. Patent No. 8,722,076 against Nevakar Injectables Inc. for alleged infringement of its leuprolide acetate formulation.
• Nevakar's primary defense is the invalidity of the '076 patent, citing grounds such as anticipation and obviousness.
• Technical arguments center on the specific composition, polymer matrix, and release characteristics of the leuprolide acetate formulations.
• The outcome will determine Nevakar's ability to launch its generic product and impact market exclusivity and pricing for leuprolide acetate.

Frequently Asked Questions

1. What is the specific therapeutic area for leuprolide acetate formulations at issue? Leuprolide acetate is commonly used in treating conditions such as prostate cancer, endometriosis, uterine fibroids, and central precocious puberty, by suppressing the production of sex hormones.

2. How does the claim construction phase impact the litigation? Claim construction, often conducted through a Markman hearing, defines the legal meaning and scope of the patent claims. A broader construction favors the patent holder (Endo), potentially widening the scope of infringement, while a narrower construction favors the accused infringer (Nevakar), potentially limiting the scope of the patent.

3. Are there other patents or legal avenues that could affect the market for this product? Yes, depending on the specific product and its development history, other patents (e.g., process patents, polymorph patents) could exist. Additionally, the Hatch-Waxman Act framework, including Paragraph IV certifications and potential 180-day exclusivity for first filers, plays a significant role in the generic drug approval and market entry process.

4. What is the significance of "willful infringement" in this context? If a court finds willful infringement, it means Nevakar knew about the '076 patent and deliberately infringed it. This can lead to enhanced damages for Endo, potentially up to treble the amount of compensatory damages, and an award of attorney's fees.

5. What is the typical duration for a patent infringement lawsuit of this complexity? Patent infringement lawsuits can be lengthy, often lasting from two to five years from filing to final resolution, particularly if appeals are involved. The duration is influenced by the complexity of the technology, the number of disputed issues, and the court's docket.

---

Citations

[1] U.S. District Court for the District of Delaware. (2021). Endo Ventures Limited v. Nevakar Injectables Inc., Case No. 1:21-cv-01186. Complaint for Patent Infringement.